Research Paper Volume 13, Issue 20 pp 23672—23688
Differences in and verification of genetic alterations in chemotherapy and immunotherapy for metastatic melanoma
Figure 1. Cumulative number of survived events in patients with metastatic melanoma undergoing chemotherapy and immunotherapy. (A–C) The Log-rank test for overall survival, disease specific survival, and progression-free interval survival curves of the chemotherapy and immunotherapy groups. (D) Survival curves of overall survival of male and female patients.